

# Sander Canisius

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9042959/publications.pdf>

Version: 2024-02-01

20  
papers

2,085  
citations

567281

15  
h-index

794594

19  
g-index

20  
all docs

20  
docs citations

20  
times ranked

4788  
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments. <i>Clinical Cancer Research</i> , 2022, 28, 960-971.	7.0	4
2	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	5.0	7
3	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021, 11, 19787.	3.3	2
4	Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients. <i>Breast</i> , 2021, 60, 230-237.	2.2	0
5	Breast cancer risk factors and their effects on survival: a Mendelian randomisation study. <i>BMC Medicine</i> , 2020, 18, 327.	5.5	40
6	Endonuclease FEN1 Coregulates ER $\pm$ Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer. <i>Cancer Research</i> , 2020, 80, 1914-1926.	0.9	23
7	Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression. <i>Oncogene</i> , 2020, 39, 4118-4131.	5.9	19
8	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020, 11, 312.	12.8	30
9	Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?. <i>European Journal of Radiology</i> , 2019, 121, 108705.	2.6	9
10	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	6.4	52
11	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. <i>Oncotarget</i> , 2016, 7, 80140-80163.	1.8	31
12	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 1303-1317.	5.1	51
13	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016, 48, 374-386.	21.4	125
14	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015, 17, 58.	5.0	26
15	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20.	6.2	76
16	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015, 47, 373-380.	21.4	513
17	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. <i>American Journal of Human Genetics</i> , 2015, 97, 22-34.	6.2	37
18	Identification of Novel Genetic Markers of Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	56

#	ARTICLE	IF	CITATIONS
19	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1680-1691.	2.5	24
20	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	21.4	960